Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-859: pembrolizumab plus chemotherapy vs placebo plus chemotherapy in HER2-negative gastric/GEJ adenocarcinoma
2023-508890-10-00Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 32
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Pembrolizumab plus chemotherapy with Placebo plus chemotherapy (2 arms). Primary endpoints: Overall survival in all participants, Overall survival in participants with PD-L1 CPS ≥1 and 1 more. Started Apr 2024; status: completed.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2023-508890-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508890-10-00.